Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | PGR | P06401 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL565747 | 0.80 | PGR (0.37) | LMNATAS2R14ESR1MAPTPGR | |
| SCHEMBL566080 | 0.71 | ESR1 (0.47) | LMNATAS2R14ESR1MAPTPGR | |
| SCHEMBL665429 | 0.69 | TAS2R14 (0.60) | TAS2R14ESR1PGRALDH1A1 | |
| SCHEMBL566524 | 0.68 | S1PR1 (0.43) | LMNATAS2R14MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL10186896 | 0.68 | PGR (0.70) | TAS2R14ESR1MAPTPGRNR1H3 | |
| SCHEMBL177154 | 0.65 | S1PR5 (0.49) | TAS2R14 | |
| SCHEMBL177536 | 0.65 | PGR (0.55) | LMNAESR1PGRALDH1A1MCOLN3 | |
| SCHEMBL15512145 | 0.63 | HSD17B1 (0.41) | LMNATAS2R14ESR1MAPTPGR | |
| SCHEMBL177470 | 0.63 | HSD17B1 (0.42) | LMNAESR1MAPTMEN1KMT2A | |
| SCHEMBL7822894 | 0.62 | HIF1A (0.57) | PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181182-B2 | S1P receptors modulators | AKAAL PHARMA PTY LTD (AU) | 2015-11-10 | — | — | US | disclosed |
| US-20120034270-A1 | S1P Receptors Modulators | AKAAL PHARMA PTY LTD (AU) | 2012-02-09 | — | — | US | disclosed |
| EP-2344446-A1 | S1P RECEPTORS MODULATORS | Akaal Pharma Pty Ltd (AU) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010042998-A1 | S1P RECEPTORS MODULATORS | AKAAL PHARMA PTY LTD (AU) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034270-A1 | S1P Receptors Modulators | S1PR1, S1PR5, S1PR3 | LMNA 3090/4885TAS2R14 2779/4885ESR1 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.